Literature DB >> 32238588

Antiviral Activity and Adaptive Evolution of Avian Tetherins.

Veronika Krchlíková1, Helena Fábryová2, Tomáš Hron1, Janet M Young3, Anna Koslová1, Jiří Hejnar1, Klaus Strebel4, Daniel Elleder5.   

Abstract

Tetherin/BST-2 is an antiviral protein that blocks the release of enveloped viral particles by linking them to the membrane of producing cells. At first, BST-2 genes were described only in humans and other mammals. Recent work identified BST-2 orthologs in nonmammalian vertebrates, including birds. Here, we identify the BST-2 sequence in domestic chicken (Gallus gallus) for the first time and demonstrate its activity against avian sarcoma and leukosis virus (ASLV). We generated a BST-2 knockout in chicken cells and showed that BST-2 is a major determinant of an interferon-induced block of ASLV release. Ectopic expression of chicken BST-2 blocks the release of ASLV in chicken cells and of human immunodeficiency virus type 1 (HIV-1) in human cells. Using metabolic labeling and pulse-chase analysis of HIV-1 Gag proteins, we verified that chicken BST-2 blocks the virus at the release stage. Furthermore, we describe BST-2 orthologs in multiple avian species from 12 avian orders. Previously, some of these species were reported to lack BST-2, highlighting the difficulty of identifying sequences of this extremely variable gene. We analyzed BST-2 genes in the avian orders Galliformes and Passeriformes and showed that they evolve under positive selection. This indicates that avian BST-2 is involved in host-virus evolutionary arms races and suggests that BST-2 antagonists exist in some avian viruses. In summary, we show that chicken BST-2 has the potential to act as a restriction factor against ASLV. Characterizing the interaction of avian BST-2 with avian viruses is important in understanding innate antiviral defenses in birds.IMPORTANCE Birds are important hosts of viruses that have the potential to cause zoonotic infections in humans. However, only a few antiviral genes (called viral restriction factors) have been described in birds, mostly because birds lack counterparts of highly studied mammalian restriction factors. Tetherin/BST-2 is a restriction factor, originally described in humans, that blocks the release of newly formed virus particles from infected cells. Recent work identified BST-2 in nonmammalian vertebrate species, including birds. Here, we report the BST-2 sequence in domestic chicken and describe its antiviral activity against a prototypical avian retrovirus, avian sarcoma and leukosis virus (ASLV). We also identify BST-2 genes in multiple avian species and show that they evolve rapidly in birds, which is an important indication of their relevance for antiviral defense. Analysis of avian BST-2 genes will shed light on defense mechanisms against avian viral pathogens.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  avian retrovirus; chicken; restriction factor; tetherin

Mesh:

Substances:

Year:  2020        PMID: 32238588      PMCID: PMC7307100          DOI: 10.1128/JVI.00416-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Mx is dispensable for interferon-mediated resistance of chicken cells against influenza A virus.

Authors:  Benjamin Schusser; Antje Reuter; Alexander von der Malsburg; Nicola Penski; Steffen Weigend; Bernd Kaspers; Peter Staeheli; Sonja Härtle
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Prediction of potential GPI-modification sites in proprotein sequences.

Authors:  B Eisenhaber; P Bork; F Eisenhaber
Journal:  J Mol Biol       Date:  1999-09-24       Impact factor: 5.469

3.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

Review 5.  Human immunodeficiency virus, restriction factors, and interferon.

Authors:  Stuart Neil; Paul Bieniasz
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

6.  Early Vertebrate Evolution of the Host Restriction Factor Tetherin.

Authors:  Elena Heusinger; Silvia F Kluge; Frank Kirchhoff; Daniel Sauter
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

7.  Inhibition of avian tumor virus replication by CCCH-type zinc finger antiviral protein.

Authors:  Mingjun Zhu; Xiaoqian Ma; Xiyao Cui; Jing Zhou; Chengui Li; Libo Huang; Yingli Shang; Ziqiang Cheng
Journal:  Oncotarget       Date:  2017-07-19

8.  Tetherin inhibits HIV-1 release by directly tethering virions to cells.

Authors:  David Perez-Caballero; Trinity Zang; Alaleh Ebrahimi; Matthew W McNatt; Devon A Gregory; Marc C Johnson; Paul D Bieniasz
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

9.  Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M.

Authors:  Caroline Blondeau; Annegret Pelchen-Matthews; Petra Mlcochova; Mark Marsh; Richard S B Milne; Greg J Towers
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

10.  The interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus.

Authors:  Kelsey A Haugh; Natalia Shalginskikh; Shoko Nogusa; Anna Marie Skalka; Richard A Katz; Siddharth Balachandran
Journal:  Virol J       Date:  2014-05-28       Impact factor: 4.099

View more
  2 in total

1.  The Present and Future of Virology in the Czech Republic-A New Phoenix Made of Ashes?

Authors:  Tomas Ruml
Journal:  Viruses       Date:  2022-06-14       Impact factor: 5.818

Review 2.  Mammalian and Avian Host Cell Influenza A Restriction Factors.

Authors:  Joe McKellar; Antoine Rebendenne; Mélanie Wencker; Olivier Moncorgé; Caroline Goujon
Journal:  Viruses       Date:  2021-03-22       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.